Switch theme
Sign up to access all valuation multiples
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
2014
12.7K+
LTM Revenue $2.7B
LTM EBITDA $904M
$13.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Wuxi Biologics has a last 12-month revenue of $2.7B and a last 12-month EBITDA of $904M.
In the most recent fiscal year, Wuxi Biologics achieved revenue of $2.2B and an EBITDA of $707M.
Wuxi Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wuxi Biologics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.0B | $2.2B | $2.5B | $2.7B | XXX |
| Gross Profit | $621M | $864M | $878M | XXX | XXX |
| Gross Margin | 32% | 39% | 35% | XXX | XXX |
| EBITDA | $800M | $707M | $824M | $904M | XXX |
| EBITDA Margin | 41% | 32% | 33% | 34% | XXX |
| Net Profit | $436M | $568M | $437M | XXX | XXX |
| Net Margin | 22% | 26% | 18% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Wuxi Biologics's stock price is HKD 26 (or $3).
Wuxi Biologics has current market cap of HKD 107B (or $13.7B), and EV of HKD 101B (or $13.0B).
See Wuxi Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.0B | $13.7B | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Wuxi Biologics has market cap of $13.7B and EV of $13.0B.
Wuxi Biologics's trades at 5.1x LTM EV/Revenue multiple, and 15.4x LTM EBITDA.
Analysts estimate Wuxi Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Wuxi Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $13.0B | XXX | XXX | XXX |
| EV/Revenue | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | XXX | XXX |
| P/E | 30.0x | XXX | XXX | XXX |
| P/E/Growth | 1.6x | XXX | XXX | XXX |
| EV/FCF | 318.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpWuxi Biologics's NTM/LTM revenue growth is 14%
Wuxi Biologics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $24K for the same period.
Over next 12 months, Wuxi Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Wuxi Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Wuxi Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 47% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $24K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 14% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wuxi Biologics acquired XXX companies to date.
Last acquisition by Wuxi Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Wuxi Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Wuxi Biologics founded? | Wuxi Biologics was founded in 2014. |
| Where is Wuxi Biologics headquartered? | Wuxi Biologics is headquartered in Hong Kong. |
| How many employees does Wuxi Biologics have? | As of today, Wuxi Biologics has 12.7K+ employees. |
| Who is the CEO of Wuxi Biologics? | Wuxi Biologics's CEO is Dr. Chen Zhisheng. |
| Is Wuxi Biologics publicy listed? | Yes, Wuxi Biologics is a public company listed on HKG. |
| What is the stock symbol of Wuxi Biologics? | Wuxi Biologics trades under 02269 ticker. |
| When did Wuxi Biologics go public? | Wuxi Biologics went public in 2017. |
| Who are competitors of Wuxi Biologics? | Similar companies to Wuxi Biologics include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Wuxi Biologics? | Wuxi Biologics's current market cap is $13.7B |
| What is the current revenue of Wuxi Biologics? | Wuxi Biologics's last 12-month revenue is $2.7B. |
| What is the current EBITDA of Wuxi Biologics? | Wuxi Biologics's last 12-month EBITDA is $904M. |
| What is the current EV/Revenue multiple of Wuxi Biologics? | Current revenue multiple of Wuxi Biologics is 5.1x. |
| What is the current EV/EBITDA multiple of Wuxi Biologics? | Current EBITDA multiple of Wuxi Biologics is 15.4x. |
| What is the current revenue growth of Wuxi Biologics? | Wuxi Biologics revenue growth between 2023 and 2024 was 13%. |
| Is Wuxi Biologics profitable? | Yes, Wuxi Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
